Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | USP9X | Q93008 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6162211 | 0.99 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL6544495 | 0.87 | HSD11B1 (0.73) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL4630666 | 0.87 | HSD11B1 (0.79) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| Water SCHEMBL6544000 | 0.85 | HSD11B1 (0.77) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| Water SCHEMBL6544001 | 0.85 | HSD11B1 (0.77) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| Hydrochloric Acid SCHEMBL6161721 | 0.85 | HSD11B1 (0.77) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL2479508 | 0.85 | HSD11B1 (0.79) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL6543280 | 0.85 | HSD11B1 (0.79) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL2471436 | 0.84 | HSD11B1 (0.57) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 | |
| SCHEMBL5371532 | 0.84 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1TSHRLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-112955215-B | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| EP-3873600-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2021-09-08 | — | — | EP | disclosed |
| CN-112955215-A | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2004-11-04 | — | — | US | disclosed |
| US-6710042-B2 | PIPERIDINE DERIVATIVES; TREATMENT OF PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-03-23 | — | — | US | disclosed |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6291672-B1 | FOR THE PREPARATION OF DRUGS USEFUL IN THERAPY OF PSYCHIATRIC DISEASES, DISEASES OF PSYCHOSOMATIC ORIGIN, HYPERTENSION | SANOFI-SYNTHELABO (FR) | 2001-09-18 | — | — | US | disclosed |
| US-6028082-A | FOR TRATING PSYCHOLOGICAL DISORDERS | SANOFI-SYNTHELABO (FR) | 2000-02-22 | — | — | US | disclosed |
| US-5925642-A | ANTITUMOR, ANTIMETASTASIS AGENTS; DRUG RESISTANCE MODULATORS; SYNERGISTIC MIXTURES WITH ANTIBIOTICS AND CYTOSTATIC AGENTS; SIDE EFFECT REDUCTION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-07-20 | — | — | US | disclosed |
| CN-1181069-A | 5 -(4 -subst. -piperidinyl -1) -3 -aryl -pentanoic acid derivatives as tachykinin receptor antagonist | ZENECA LTD (GB) | 1998-05-06 | — | — | CN | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220223-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | SMN1; SMN2 4420/4885ALDH1A1 3554/4885TSHR 487/4885 |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | SMN1; SMN2 1024/4885ALDH1A1 455/4885TSHR 1733/4885 |
| US-20020049329-A1 | Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them | TACR2, BDKRB2, ACKR3 | SMN1; SMN2 4420/4885ALDH1A1 3554/4885TSHR 487/4885 |
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | ARSA, SULT1A1, SULT2A1 | SMN1; SMN2 1024/4885ALDH1A1 455/4885TSHR 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.